Expert Interview
Examination of Edgewise Therapeutics’ Pipeline for Rare Muscle Disorders
Ticker(s): EWTXA neurologist/ neuromuscular specialist with knowledge about Edgewise Therapeutics’ Developing Treatments.
Please tell us about your clinical experience. How many patients with muscle disorders do you see on a yearly basis?
What are the most commonly used Corticosteroids and Muscle Relaxants prescribed for muscular dystrophy?
Can you give us your impression of the company’s preclinical models in DMD?
Can you talk to us about the company’s Therapeutic Hypothesis of Selectively Limiting Contraction in Susceptible Fast Muscle Fibers in order to Preserve Muscle Function. Is this reduction in fast fiber contraction sufficient to prevent muscle breakdown?
How realistic is their goal of 5-20% reduction of muscle contraction in susceptible type II (fast) muscle fibers with a selective myosin inhibitor?
Added By: slingshot_insightsWhat’s your take on EDG-5506 Improvement Results in mdx Mice, DBA/2J-mdx Mice and GRMD preclinical models?
What is your impression on EDG-5506 ability to Reduce mdx Mouse Creatine Kinase Response After Strength-Testing without Altering Performance, and Preventing Edema and Muscle Necrosis that Result from Muscle Membrane Disruption in DMD?
15 Months Dosing of DBA/2J mdx Mice Demonstrated Lower Cardiac Fibrosis Compared to Vehicle Controls and EDG-5506 Led to a Reduction in the Incidence of Cardiac Hypertrophy. Can you please discuss these results?
How likely would you be to prescribe EDG-5506, judging from the preclinical data available so far?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
